Published in J Vis Exp on February 02, 2011
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood (2014) 1.62
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy (2012) 1.27
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 1.07
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol (2015) 0.94
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys. J Immunol (2014) 0.90
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother (2013) 0.86
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood (2014) 0.85
HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms. Am J Pathol (2012) 0.83
In vivo monitoring of natural killer cell trafficking during tumor immunotherapy. Magn Reson Insights (2014) 0.83
Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol (2013) 0.82
Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant (2015) 0.81
Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS One (2015) 0.80
Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). J Vis Exp (2013) 0.80
Suppression of a Natural Killer Cell Response by Simian Immunodeficiency Virus Peptides. PLoS Pathog (2015) 0.79
NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy (2012) 0.79
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant (2016) 0.78
Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma. Am J Pathol (2016) 0.77
Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun (2016) 0.77
Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Vet Immunol Immunopathol (2013) 0.77
Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients. Biomed Rep (2014) 0.77
"Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy. Biomed Res Int (2015) 0.77
Positive and negative regulation by NK cells in cancer. Crit Rev Oncog (2014) 0.76
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases. Biol Blood Marrow Transplant (2015) 0.76
A Novel Method for Assessment of Natural Killer Cell Cytotoxicity Using Image Cytometry. PLoS One (2015) 0.76
NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells. Front Immunol (2016) 0.75
Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Front Immunol (2017) 0.75
Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology (2017) 0.75
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol (2017) 0.75
TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res (2016) 0.75
Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells. PLoS One (2017) 0.75
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology (2017) 0.75
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol (2001) 1.57
Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion (2007) 1.49
Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy (2004) 1.31
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant (2008) 1.30
Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr (2005) 1.26
Replicative potential of human natural killer cells. Br J Haematol (2009) 1.19
Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol (2007) 1.15
Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15. Tissue Antigens (2010) 1.04
Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant (2006) 1.00
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther (2010) 1.64
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res (2011) 1.53
Strain and virulence diversity in the mouse pathogen Chlamydia muridarum. Infect Immun (2009) 1.36
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther (2012) 1.29
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood (2013) 1.17
Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med (2013) 1.14
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One (2013) 1.14
Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother (2013) 1.13
Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther (2013) 1.09
Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09
Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood (2012) 1.07
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep (2012) 1.07
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One (2013) 1.02
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest (2016) 0.96
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol (2013) 0.92
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer (2013) 0.90
Immunosuppression may be present within condyloma acuminata. J Am Acad Dermatol (2008) 0.90
The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res (2013) 0.89
Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother (2013) 0.86
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells. Cancer Immunol Immunother (2007) 0.85
C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet (2007) 0.85
Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med (2015) 0.85
A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices (2010) 0.83
Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb) (2013) 0.82
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer (2014) 0.80
Erythroid cells in immunoregulation: characterization of a novel suppressor factor. Immunol Lett (2004) 0.79
NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy (2012) 0.79
Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol (2013) 0.78
Natural killer cells for osteosarcoma. Adv Exp Med Biol (2014) 0.77
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med (Berl) (2012) 0.77
Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother (2016) 0.76
Rotavirus vaccines. N Engl J Med (2006) 0.75